本文已被:浏览 465次 下载 168次
投稿时间:2026-04-29 网络发布日期:2026-09-24
投稿时间:2026-04-29 网络发布日期:2026-09-24
中文摘要: 目的 评估磁共振成像(MRI)参数联合血清成纤维细胞生长因子受体4(FGFR4)、核因子-κB受体活化因子配体(RANKL)对乳腺癌患者新辅助化疗(NACT)疗效的预测价值,为临床应用提供新思路。方法 回顾性分析2021 年10 月至2024 年10 月于营口市中心医院行NACT 联合乳腺癌改良根治术或保乳术的133 例患者的临床资料,以NACT 治疗后的病理评估结果,分为NACT 有效组(n=62)及NACT 无效组(n=71)。收集患者乳腺磁共振动态增强扫描相关参数值;利用酶联免疫吸附法检测血清FGFR4、RANKL水平。采用多因素logistic回归模型分析NACT 疗效的影响因素;采用受试者工作特征(ROC)曲线评估血清FGFR4、RANKL对NACT疗效的预测价值。结果 两组患者雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、Ki-67表达以及分子分型间比较差异有统计学意义(P<0.05)。NACT 治疗4个疗程后,NACT 有效组的Kep、Ktrans、FGFR4、RANKL 水平低于NACT无效组,ADC高于NACT无效组(P<0.05)。Kep、Ktrans、ADC、FGFR4、RANKL水平及其联合预测NACT疗效的曲线下面积(AUC)分别为0.831、0.871、0.739、0.852、0.808、0.967,联合预测效能优于单一指标(Z 联合-Kep=3.599,P<0.01;Z 联合-Ktrans=2.781,P=0.005;Z 联合-ADC=5.301,P<0.01;Z 联合-FGFR4=3.283,P=0.001;Z 联合-RANKL=3.918,P<0.01)。结论 MRI参数、血清FGFR4及RANKL对于预测乳腺癌NACT疗效均有一定的临床应用价值,其联合检测可提高预测效能。
中文关键词: 乳腺癌 新辅助化疗 磁共振成像 成纤维细胞生长因子受体4 核因子-κB受体活化因子配体
Abstract:Objective To evaluate the predictive value of magnetic resonance imaging(MRI)parameters combined with serum fibroblast growth factor receptor 4(FGFR4)and receptor activator of nuclear factor-κB ligand(RANKL)for the efficacy of neoadjuvant chemotherapy(NACT)in patients with breast cancer,aiming to offer new ideas for clinical applications. Methods The clinical data of 133 breast cancer patients who received NACT followed by modified radical mastectomy or breast-conserving surgery at Yingkou Central Hospital from October 2021 to October 2024 were retrospectively analyzed. According to the pathological evaluation after NACT,patients were divided into the NACT effective group(n=62)and the NACT ineffective group(n=71). Parameters of breast dynamic contrast - enhanced magnetic resonance scan were collected. Serum FGFR4 and RANKL levels were detected by enzyme-linked immunosorbent assay. Multivariate logistic regression was performed to screen the influencing factors for NACT efficacy. Receiver operating characteristic(ROC)curve analysis was used to assess the predictive value of serum FGFR4 and RANKL for NACT efficacy. Results There were statistically significant differences in estrogen receptor (ER),progesterone receptor(PR),human epidermal growth factor receptor 2(HER-2),Ki-67 expression and molecular subtypes between the two groups(P<0.05). After 4 cycles of NACT,the levels of Kep,Ktrans,FGFR4 and RANKL in the NACT effective group were significantly lower,while the ADC value was significantly higher compared to the NACT ineffective group(P<0.05). The area under the curve(AUC)of Kep,Ktrans,ADC,FGFR4,RANKL and their combination for predicting NACT efficacy were 0.831,0.871,0.739,0.852,0.808 and 0.967,respectively. The predictive efficiency of the combined model was significantly superior to that of each single indicator(Zcombination-Kep=3.599,P<0.01;Zcombination-Ktrans=2.781,P=0.005;Zcombination - ADC=5.301,P<0.01;Zcombination - FGFR4=3.283,P=0.001;Zcombination - RANKL=3.918,P<0.01). Conclusion MRI parameters,serum FGFR4 and RANKL have certain clinical value in predicting NACT efficacy for breast cancer,and the combined detection of the three indicators can effectively improve the predictive efficiency.
keywords: Breast cancer Neoadjuvant chemotherapy Magnetic resonance imaging Fibroblast growth factor receptor 4 Receptor activator of nuclear factor-κB ligand
文章编号: 中图分类号:R737.9 文献标志码:A
基金项目:
附件
| Author Name | Affiliation |
| YOU Yingning,ZHENG Pengyu | Yingkou Central Hospital Medical Imaging Center,Yingkou,Liaoning 115000,China |
引用文本:
由英宁,郑鹏宇.MRI参数联合血清FGFR4、RANKL对乳腺癌新辅助化疗疗效的预测价值[J].中国临床研究,2026,39(9):1356-1360.
由英宁,郑鹏宇.MRI参数联合血清FGFR4、RANKL对乳腺癌新辅助化疗疗效的预测价值[J].中国临床研究,2026,39(9):1356-1360.
